American College of Cardiology Annual Scientific Session and Expo

American College of Cardiology 2011

Cangrelor Demonstrates Reduction in Early Ischemic Events in PCI Patients Compared with Clopidogrel

Cangrelor, an intravenous potent, rapid-acting P2Y12 inhibitor, reduces the risk of early ischemic events compared with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention, investigators reported during ACC.11, the American College of Cardiology’s 60th Annual Scientific Sessions.

Efficacy and Safety Profile of Ticagrelor in ACS Found to Be Independent of Age as Compared With Clopidogrel

Ticagrelor demonstrated comparable efficacy and safety compared with clopidogrel in elderly patients with acute coronary syndrome who are at higher risk for recurrent ischemic events, death, and treatment-related complications, according to study data presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

The ACC/AHA Guidelines: What’s New

New recommendations are indicated for the treatment of extracranial carotid and vertebral artery disease (ECVD), UA/NSTEMI, and hypertrophic cardiomyopathy (HCM), according to several researchers who discussed the recent 2011 changes to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines at a symposium during ACC.11, the American College of Cardiology’s 60th Scientific Session.

Rivaroxaban Compares Favorably With Enoxaparin for VTE Prevention in Acute Conditions But Demonstrates No Net Clinical Benefit

Rivaroxaban is non-inferior to enoxaparin in short-term use and superior in long-term use for the prevention of venous thromboembolism (VTE) in acutely ill medical patients, but demonstrates weaker safety outcomes, according to results of the MAGELLAN trial presented today at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Valsartan and Amlodipine Equally Effective in Patients with Hypertension and Glucose Intolerance

Angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are equally effective at improving cardiovascular outcomes in patients with hypertension and glucose intolerance, according to results of the NAGOYA Heart Study, the first randomized study to compare the two drug classes presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

In Elderly Hypertensive Patients, Combination ARB and Calcium Channel Blocker Produces Similar Outcomes to High-Dose ARB Alone

Elderly patients with hypertension have similar rates of cardiovascular events and death when treated with a combination of an angiotensin II receptor blockers (ARB) and a calcium channel blocker (CCB), according to the results of a subanalysis of the OSCAR study that were presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.